Core One Labs Proposes to Amend Outstanding Warrant Exercise Price Reduction

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Core One Labs Inc. (CSE: COOL) (OTCQX: CLABF) (FSE: LD6) (WKN: A14XHT) ("COOL" or the "Company") announces proposed amendment to an earlier reduction in the exercise price of its outstanding share purchase warrants (the "Warrants"). On or about October 28, 2019, the Company proposed to reduce the Warrant Exercises price from CAD$3.00 per share (on a post-consolidation basis) to CAD$1.25 per share (the "Warrant Repricing") (see the news release the Company disseminated on October 30, 2019). The current proposal seeks to reduce the exercise price to CAD$0.40 per share (the "Updated Warrant Repricing"). Effectiveness of the Updated Warrant Repricing is subject to the unanimous approval of the registered holders of the Warrants.

The Warrants were issued as part of the Company's oversubscribed May 9, 2019, non-brokered private placement (the "Offering") of a total of 19,424,163 pre-consolidation units (the "Units") (equal to approximately 3,237,361 post-consolidation Units). Each Unit sold as part of the Offering consisted of one common share of the Company (each a "Unit Share") and one Warrant. Each Warrant entitles the holder to purchase one additional common share (a "Warrant Share") at a pre-consolidation price of CAD$0.50 per Warrant Share, or a post-consolidation price of CAD$3.00 per Warrant Share for a period ending one May 9, 2020.

The Company's management considers the Updated Warrant Repricing to be in the best interests of the Company and its shareholders. The expiry date of the Warrants will remain May 9, 2020. However, if, at any time after the Warrant Repricing becomes effective, the closing price of the Company's common shares, as quoted by the Canadian Securities Exchange (the "Exchange"), is equal to or greater than CAD$0.51 per share for ten consecutive trading days, the expiration date of the Warrants will automatically be accelerated to the date that is 30 calendar days after the date of such ten consecutive trading day period.

Under the policies of the Exchange, the proposed Amended Warrant Repricing is subject to the unanimous consent of the registered holders of the outstanding Warrants. To secure the required consents, the Company has sent out notice of the Updated Warrant Repricing to the registered holders of all of the Warrants. If any Warrant holders have not received written notice of the proposed Warrant Repricing, the Company encourages them to contact the Company's investor relations personnel to have the notice and corresponding form of consent re-forwarded to them.

About Core One Labs Inc.

Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.

Core One Labs Inc.
Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
[email protected]

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/51836

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).